Skip to main content

EVOLUCION NATURAL, CARACTERIZACION MOLECULAR Y DISFUNCION ENDOTELIAL DE LAS NEOPLASIAS MIELOPROLIFERATIVAS QUE DEBUTAN EN FORMA DE TROMBOSIS ESPLACNICA

PI18/00205

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2018
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PRIVADA CLINIC
Execution centre HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

  • Álvarez Larrán, Alberto|||0000-0001-6387-4619
  • Garrote, Marta
  • Ferrer-Marín, Francisca|||0000-0002-9520-3243
  • Pérez-Encinas, Manuel|||0000-0001-9943-4404
  • Mata-Vazquez, M.Isabel
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Arellano-Rodrigo, Eduardo|||0000-0001-6236-7826
  • Gómez, Montse
  • García, Regina
  • García Gutiérrez, Valentín|||0000-0003-4752-0815
  • Gasior Kabat, Mercedes
  • Cuevas, Beatriz|||0000-0001-7555-3361
  • Angona, Anna|||0000-0002-0965-9501
  • Gómez-Casares, María Teresa
  • Martínez, Clara
  • Magro, Elena
  • Ayala, Rosa|||0000-0002-2699-8353
  • Del Orbe Barreto, Rafael Andrés|||0000-0002-1240-1958
  • Pérez-López, Raúl
  • Fox, Maria Laura|||0000-0002-0062-6607
  • Raya, José-Maria
  • Guerrero, Lucía
  • García-Hernández, Carmen
  • Caballero, Gonzalo
  • Murillo, Ilda
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Ramírez, M.José
  • Carreño-Tarragona, Gonzalo|||0000-0002-9570-5542
  • Hernandez-Boluda, Juan Carlos|||0000-0002-4289-3113
  • Pereira, Aarturo
Background: Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown. Methods: A retrospective, real-world analysis was performed on the outcomes of 377 patients with resistance/intolerance to hydroxyurea from the Spanish Registry of Polycythemia Vera according to subsequent treatment with ruxolitinib (n = 105) or the best available therapy (BAT; n = 272). Survival probabilities and rates of thrombosis, hemorrhage, acute myeloid leukemia, myelofibrosis, and second primary cancers were calculated according to treatment. To minimize biases in treatment allocation, all results were adjusted by a propensity score for receiving ruxolitinib or BAT. Results: Patients receiving ruxolitinib had a significantly lower rate of arterial thrombosis than those on BAT (0.4% vs 2.3% per year; P =.03), and this persisted as a trend after adjustment for the propensity to have received the drug (incidence rate ratio, 0.18; 95% confidence interval, 0.02-1.3; P =.09). There were no significant differences in the rates of venous thrombosis (0.8% and 1.1% for ruxolitinib and BAT, respectively; P =.7) and major bleeding (0.8% and 0.9%, respectively; P =.9). Ruxolitinib exposure was not associated with a higher rate of second primary cancers, including all types of neoplasia, noncutaneous cancers, and nonmelanoma skin cancers. After a median follow-up of 3.5 years, there were no differences in survival or progression to acute leukemia or myelofibrosis between the 2 groups. Conclusions: The results suggest that ruxolitinib treatment for PV patients with resistance/intolerance to hydroxyurea may reduce the incidence of arterial thrombosis. Lay Summary: Ruxolitinib is better than other available therapies in achieving hematocrit control and symptom relief in patients with polycythemia vera who are resistant/intolerant to hydroxyurea, but we still do not know whether ruxolitinib provides an additional benefit in preventing thrombosis or disease progression. We retrospectively studied the outcomes of 377 patients with resistance/intolerance to hydroxyurea from the Spanish Registry of Polycythemia Vera according to whether they subsequently received ruxolitinib (n = 105) or the best available therapy (n = 272). Our findings suggest that ruxolitinib could reduce the incidence of arterial thrombosis, but a disease-modifying effect could not be demonstrated for ruxolitinib in this patient population.